Notice of Closed Meeting: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel, 18848 [2019-08929]
Download as PDF
<![CDATA[
18848
Federal Register / Vol. 84, No. 85 / Thursday, May 2, 2019 / Notices
prevention interventions, relatively
little scientific or systematic work has
been done to describe the nature and
level of fatal violence associated with
schools. Until NCIPC conducted the first
nationwide investigation of violent
deaths associated with schools, public
health and education officials had to
rely on limited local studies and
estimated numbers to describe the
extent of school-associated violent
death.
SAVD is an ongoing surveillance
system that draws cases from the entire
United States in an attempt to capture
all cases of school-associated violent
deaths that have occurred. Investigators
review public records and published
press reports concerning each schoolassociated violent death. For each
identified case, investigators also
contact the corresponding law
enforcement agency and speak with an
official in order to confirm or reject the
case as an SAVD, and to request a copy
of the official law enforcement report for
confirmed SAVD cases.
In past years, investigators would
interview an investigating law
enforcement official (defined as a police
officer, police chief, or district attorney),
and a school official (defined as a school
principal, school superintendent, school
counselor, school teacher, or school
support staff) who were knowledgeable
about the case in question; however,
moving forward, the interviews with
these respondents will be eliminated,
and instead CDC study personnel will
abstract data from law enforcement
reports to enter using a Data Abstraction
Tool. Data to be abstracted from the law
enforcement report include the
following: Information on both the
victim and alleged offender(s)—
including demographic data, their
criminal records, and their relationship
to one another; the time and location of
the incident precipitating the fatality;
the circumstances, motive, and method
of the fatal injury; and the security and
violence prevention activities in the
school and community where the death
occurred, before and after the fatal
injury event. The revised data collection
process eliminating the use of telephone
interviews will reduce respondents’
burden greatly.
All data are secured through the use
of technical, physical, and
administrative controls. Hard copies of
data are kept under lock and key in
secured offices, located in a secured
facility that can be accessed only by
presenting the appropriate credentials.
Digital data are password protected and
then stored (and backed up routinely)
onto a secure Local Area Network that
can only be accessed by individuals
who have been appropriately
authorized. Study data are reported in
the aggregate, such that no individual
case can be identified from the reports.
There are no costs to the respondents
other than their time. The total
estimated annual burden hours are 17.
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
Law Enforcement Officer ................................
Law Enforcement Case Confirmation Script ..
Letter to Local Law Enforcement Officials .....
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2019–08931 Filed 5–1–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel
khammond on DSKBBV9HB2PROD with NOTICES
Number of
respondents
Type of respondent
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Chief Operating Officer, CDC,
pursuant to Public Law 92–463. The
grant applications and the discussions
could disclose confidential trade secrets
or commercial property such as
VerDate Sep<11>2014
18:51 May 01, 2019
Jkt 247001
patentable material, and personal
information concerning individuals
associated with the grant applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
PS15–001SUPP, Positive Health Check
Evaluation Trial.
Date: June 27, 2019.
Time: 10:00 a.m.–5:00 p.m., (EDT).
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
Clifton Road NE, Mailstop E60, Atlanta,
Georgia 30329, (404) 718–8833, gca5@
cdc.gov.
The Chief Operating Officer, Centers
for Disease Control and Prevention, has
been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
50
50
Average
burden per
response
(in hours)
1
1
5/60
15/60
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2019–08929 Filed 5–1–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–N–1346]
Development of Antiviral Drugs for the
Treatment of Adenoviral Infection in
Immunocompromised Patients; Public
Workshop; Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice of public workshop;
request for comments.
ACTION:
The Food and Drug
Administration (FDA, the Agency, or
we) is announcing the following public
workshop entitled ‘‘Development of
Antiviral Drugs for the Treatment of
Adenoviral Infection in
SUMMARY:
E:\FR\FM\02MYN1.SGM
02MYN1
]]>Agencies
[Federal Register Volume 84, Number 85 (Thursday, May 2, 2019)]
[Notices]
[Page 18848]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-08929]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting: Disease, Disability, and Injury
Prevention and Control Special Emphasis Panel
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Chief Operating
Officer, CDC, pursuant to Public Law 92-463. The grant applications and
the discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)--PS15-001SUPP, Positive Health
Check Evaluation Trial.
Date: June 27, 2019.
Time: 10:00 a.m.-5:00 p.m., (EDT).
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600 Clifton Road NE, Mailstop E60,
Atlanta, Georgia 30329, (404) 718-8833, [email protected].
The Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2019-08929 Filed 5-1-19; 8:45 am]
BILLING CODE 4163-18-P
